Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Carmell Therapeutics Corp...

    NASDAQ: CTCX · Real-Time Price · USD
    0.20
    0.01 (2.77%)
    At close: Mar 07, 2025, 3:55 PM

    Carmell Therapeutics Statistics

    Share Statistics

    Carmell Therapeutics has 30.12M shares outstanding. The number of shares has increased by 46.44% in one year.

    Shares Outstanding

    n/a
    		 30.12M

    Shares Change (YoY)

    n/a
    		 46.44%

    Shares Change (QoQ)

    n/a
    		 44.08%

    Owned by Institutions (%)

    n/a
    		 n/a

    Shares Floating

    n/a
    		 14.74M

    Failed to Deliver (FTD) Shares

    n/a
    		 1,923

    FTD / Avg. Volume

    n/a
    		 0.02%

    Short Selling Information

    Short Interest

    n/a
    		 n/a

    Short % of Shares Out

    n/a
    		 n/a

    Short % of Float

    n/a
    		 n/a

    Short Ratio (days to cover)

    n/a
    		 n/a

    Valuation Ratios

    The PE ratio is -2.72 and the forward PE ratio is null. Carmell Therapeutics's PEG ratio is -0.01.

    PE Ratio

    n/a
    		 -2.72

    Forward PE

    n/a
    		 n/a

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 n/a

    PB Ratio

    n/a
    		 1.7

    P/FCF Ratio

    n/a
    		 -5.01

    PEG Ratio

    n/a
    		 -0.01
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Carmell Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 1.63, with a Debt / Equity ratio of 0.09.

    Current Ratio

    n/a
    		 1.63

    Quick Ratio

    n/a
    		 1.63

    Debt / Equity

    n/a
    		 0.09

    Debt / EBITDA

    n/a
    		 -0.14

    Debt / FCF

    n/a
    		 -0.25

    Interest Coverage

    n/a
    		 -5.87

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 $-1,716,120.78

    Employee Count

    n/a
    		 9

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 -760.16K

    Effective Tax Rate

    n/a
    		 4.69%

    Stock Price Statistics

    The stock price has increased by -90.05% in the last 52 weeks. The beta is 0.51, so Carmell Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.51

    52-Week Price Change

    n/a
    		 -90.05%

    50-Day Moving Average

    n/a
    		 0.25

    200-Day Moving Average

    n/a
    		 0.55

    Relative Strength Index (RSI)

    n/a
    		 30.21

    Average Volume (20 Days)

    n/a
    		 8,239,948

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 -124.79K

    Operating Income

    n/a
    		 -5.22M

    Net Income

    n/a
    		 -15.45M

    EBITDA

    n/a
    		 -15.19M

    EBIT

    n/a
    		 -15.32M

    Earnings Per Share (EPS)

    n/a
    		 -1.46
    Full Income Statement

    Balance Sheet

    The company has 2.91M in cash and 2.14M in debt, giving a net cash position of 776.01K.

    Cash & Cash Equivalents

    n/a
    		 2.91M

    Total Debt

    n/a
    		 2.14M

    Net Cash

    n/a
    		 776.01K

    Retained Earnings

    n/a
    		 -58.5M

    Total Assets

    n/a
    		 2.44M

    Working Capital

    n/a
    		 -4.29M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -8.35M and capital expenditures -30.47K, giving a free cash flow of -8.38M.

    Operating Cash Flow

    n/a
    		 -8.35M

    Capital Expenditures

    n/a
    		 -30.47K

    Free Cash Flow

    n/a
    		 -8.38M

    FCF Per Share

    n/a
    		 -0.76
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    CTCX does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    Currently there are no analyst rating for CTCX.

    Price Target

    n/a
    		 n/a

    Price Target Difference

    n/a
    		 n/a

    Analyst Consensus

    n/a
    		 n/a

    Analyst Count

    n/a
    		 n/a
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -52.45

    Piotroski F-Score

    n/a
    		 3

    Add to Watchlist